X4 Pharmaceuticals, Inc. Common Stock (XFOR)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
X4 Pharmaceuticals, Inc. Common Stock (XFOR) is listed on Nasdaq, where it has traded since November 16, 2017.
- Listed On
- Nasdaq
- Listed Since
- November 16, 2017
- Employees
- 45
- Market Cap
- $298M
About X4 Pharmaceuticals, Inc. Common Stock
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 86 institutions reported holding XFOR, with 99.2 million shares worth $463.0 million in aggregate. The largest reported holder was Morgan Stanley, with 9.5 million shares worth $44.2 million. Of the 5 largest holders listed below, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Morgan Stanley | 9,461,279 | $44M | Reduced 0.06% |
| FMR | 8,321,657 | $39M | Added 2.69% |
| Bain Capital Life Sciences Investors | 7,967,454 | $37M | Unchanged |
| Perceptive Advisors | 7,933,491 | $37M | Added 17.75% |
| Saturn V Capital Management | 6,973,343 | $33M | Added 8% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is XFOR?
X4 Pharmaceuticals, Inc. Common Stock (XFOR) is listed on Nasdaq, where it has traded since November 16, 2017.
Who are the largest institutional holders of XFOR?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of XFOR were Morgan Stanley, FMR and Bain Capital Life Sciences Investors.
How many institutions own XFOR?
86 institutions reported a position in XFOR for the quarter ended June 30, 2026, worth $463.0 million in total.
Did institutions buy or sell XFOR last quarter?
Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for XFOR.
Every reported institutional holder, plus insider and congressional trades in XFOR, on SentiSense.